

# Total Synthesis of the Unusual Monoterpenoid Indole Alkaloid (±)-Alstilobanine A\*\*

Yiqing Feng, Max M. Majireck, and Steven M. Weinreb\*

The monoterpene indole alkaloids, which are usually comprised of a tryptamine moiety appended to a single C<sub>9</sub>- or C<sub>10</sub>-terpenoid unit, constitute one of the largest known classes of natural products.<sup>[1]</sup> In 2004, Kam and Choo isolated a new type of monoterpene indole alkaloid, angustilodine (**1**), which contains a unique rearranged skeleton, from the leaves of the Malayan plant *Alstonia angustiloba* (Figure 1).<sup>[2]</sup> The





Figure 1. Structures of the alstilobanine alkaloids.

structure of **1** was determined by detailed spectroscopic analysis and found to include an indole appended to a *cis*-fused 2-azadecalin ring system bearing a seven-membered ether bridge. An interesting conformational feature of this molecule established by two-dimensional (2D) NMR studies is the observation that the piperidine ring exists as a boat. More recently, Morita and co-workers discovered the N-demethyl congener alstilobanine E (**2**), along with alstilobanine A (**3**), which lacks the bridging oxepane ring found in **1** and **2**, in the same plant.<sup>[3]</sup> Unlike alkaloids **1** and **2**, it was proposed that **3** has the piperidine ring in a chair conformation as shown in Figure 1. Alstilobanines A and E were found to possess modest relaxant activity against phenylephrine-induced contractions of thoracic rat aortic rings with endothelium. Herein we describe the first approach to these

alkaloids, thus culminating in a convergent total synthesis of racemic **3**.

Our synthetic strategy was predicated upon effecting two key carbon–carbon single bond constructions. The first planned transformation involved an intermolecular conjugate addition of an indole ester enolate to a 3-piperidone-derived nitrosoalkene to form the C15–C16 bond of the alkaloid.<sup>[4]</sup> The second pivotal step was to apply the methodology of Romo et al. for intramolecular  $\beta$ -lactone formation<sup>[5]</sup> to generate the requisite *cis*-2-azadecalin moiety by C19–C20 bond formation, along with the necessary functionality and three contiguous stereocenters at C15, C19, and C20. The implementation of this strategy is outlined herein.<sup>[6]</sup>

Thus, the indole 2-acetic acid methyl ester **4**<sup>[7]</sup> was first acylated at C3 using oxalyl chloride with subsequent in situ treatment of the resulting  $\alpha$ -keto acid chloride with 2-trimethylsilylethanol to afford the keto diester **5** (Scheme 1). To generate the C15–C16 bond of **3**, **5** was first converted into the dianion **6** using two equivalents of lithium hexamethyldisilazide (LiHMDS). Addition of one equivalent of the  $\alpha$ -chlorooxime **7**, derived from *N*-tosyl-3-piperidone,<sup>[8]</sup> to the dianion led to the desired coupled product as a 1.2:1



Scheme 1. Nitrosoalkene conjugate addition. TMS = trimethylsilyl, TMSE = trimethylsilylethoxy, THF = tetrahydrofuran, Ts = 4-toluenesulfonyl.

[\*] Y. Feng, M. M. Majireck, Prof. Dr. S. M. Weinreb  
Department of Chemistry, The Pennsylvania State University  
University Park, PA 16802 (USA)  
E-mail: smw@chem.psu.edu


[\*\*] We are grateful to the National Institutes of Health (GM-087733) and the National Science Foundation (CHE-1105653) for financial support of this research.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/anie.201207949>.

mixture of diastereomers **11a** and **11b** in high yield. The mixture could be separated and each isomer was isolated as a single oxime isomer with an *E* geometry. It should be noted that the mixture is of no consequence since it is subsequently corrected (see below).

We believe that this novel transformation involves the initial dehydrohalogenation of **7** by **6** to generate the transient nitrosoalkene **10** along with a monoanion derived from the indole ester. It seems likely that this intermediate is probably an equilibrium mixture of the resonance stabilized anions **8** and **9**, but the conjugate addition to **10** occurs exclusively through the latter.

To continue the synthesis, the mixture of **11a** and **11b** was first protected as the TBS ether **12** (Scheme 2). At this stage, **12** was deoxygenated by a modification of the method of




**Scheme 2.** Preparation of **17**. Cbz = benzyloxycarbonyl, DMAP = 4-(dimethylamino)pyridine, TBAF = tetra-*n*-butylammonium fluoride, TBS = *tert*-butyldimethylsilyl.

Hlasta et al.<sup>[9]</sup> Thus, the ketone was first reduced to the alcohol which was then converted into the corresponding acetate, with subsequent catalytic hydrogenation using Pd/C in *tert*-butyl alcohol/triethylamine to afford a mixture of the diastereomeric diesters **13** and **14**, which were easily separated by column chromatography.<sup>[10]</sup>

Since it was later found that these two diastereomeric systems (**13** and **14**) behave differently during the key cyclization using the protocol from Romo et al., **13** was epimerized cleanly to **14** in 70% yield upon isolation by treatment with potassium hexamethyldisilazide and subsequent quenching with aqueous ammonium chloride. The

indole nitrogen atom of **14** was then protected with a Cbz group to afford **15** whose structure was established by X-ray analysis, thus confirming both the relative stereochemistry at C15 and C16 and the *E* geometry of the O-silyloxime.<sup>[11]</sup> At this point, **15** was converted into the oxime **16** with TBAF with subsequent acidic cleavage to give the corresponding ketone **17**.<sup>[12]</sup>


Initial attempts to convert the trimethylsilyl ethyl ester **17** into the corresponding carboxylic acid with fluoride sources failed,<sup>[6]</sup> but this transformation could be performed with trifluoroacetic acid in CH<sub>2</sub>Cl<sub>2</sub> to afford the desired keto acid **18** in high yield without affecting the methyl ester **18** in high yield without affecting the methyl ester (Scheme 3).<sup>[13]</sup> With compound **18** in hand, we were prepared to attempt the second key step, that is a formal ketene/ketone-[2+2]-intramolecular cycloaddition using the protocol by Romo et al. to generate the requisite fused  $\beta$ -lactone *cis*-2-azadecalin system.



**Scheme 3.** Cyclization of **18** to give the pentacyclic  $\beta$ -lactone **19**. TFA = trifluoroacetic acid.

Therefore, treatment of **18** with 2-bromo-*N*-propylpyridinium triflate, 4-pyrrolidinopyridine (PPY), and Hünig's base in CH<sub>2</sub>Cl<sub>2</sub> containing 1.2 equivalents of acetic acid, to avoid epimerization of the C16 ester, led to the desired fused  $\beta$ -lactone system **19** needed for alstilobanine A along with a trace of the *trans*-2-azadecalin **21** (97:3 as determined by <sup>1</sup>H NMR spectroscopy) in high yield.<sup>[5b]</sup> Interestingly, when the cyclization was conducted on the C16 ester epimer of **18**, which was prepared from **13**, the major product was the undesired *trans*-2-azadecalin.


With the key intermediate **19** now in hand, we began to investigate introduction of a hydroxymethyl group at C16. Since we had found in earlier work with various other intermediates that it was not possible to generate a C16 ester enolate if a Cbz protecting group is in place on the indole nitrogen atom,<sup>[6,14]</sup> this group was removed from **19** by hydrogenolysis to afford the NH-indole ester **20**. This compound could be successfully deprotonated with two equivalents of LHMDS to generate the dianion **22**, and subsequent alkylation using monomeric formaldehyde<sup>[15]</sup> from the least hindered face produced the  $\alpha$ -hydroxymethyl ester **23** as a single diastereomer having the configuration needed for **3** (Scheme 4).<sup>[16]</sup> The stereochemistry of **23** was



**Scheme 4.** Stereoselective C16 hydroxymethylation.

established by 2D NMR analysis and was also confirmed by the fact that the  $\beta$  lactone underwent acyl migration to afford the bridged seven-membered lactone **24** upon treatment with triethylamine in  $\text{CH}_2\text{Cl}_2$ .

Since it was observed that the hydroxymethyl group of **23** tends to be lost under a variety of reaction conditions through a retro-aldol process, this functionality was protected as the TBS ether **25** (Scheme 5). The  $\beta$ -lactone moiety of **25** could then be reduced selectively with  $\text{LiBH}_4$  in THF to yield the diol ester **26**, which was converted into the iodo alcohol **27** by an Appel reaction.<sup>[17]</sup> Subsequent catalytic hydrogenation of this compound at atmospheric pressure using 10% Pd/C in a 1:1 mixture of ethyl acetate/*tert*-butyl alcohol cleanly led to the desired methyl compound **28**.<sup>[17]</sup> The N-tosyl protecting



**Scheme 5.** Completion of the synthesis of racemic alstilobanine A (**3**). Tf = trifluoromethanesulfonyl.

group of **28** was removed using magnesium metal turnings in methanol under sonication to afford **29** in good yield.<sup>[18]</sup> Once, again the structure and stereochemistry of this intermediate were confirmed by 2D NMR analysis (see the Supporting Information). Finally, removal of the TBS protecting group with HCl in methanol/chloroform afforded racemic alstilobanine A (**3**), which was isolated as its hydrochloride salt, having  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra as reported for the natural alkaloid.<sup>[3,19]</sup>

In summary, we have devised a convergent approach to a total synthesis of the novel indole alkaloid alstilobanine A (**3**). The synthesis of **3** requires about twenty operations starting from the indole methyl ester **4**. Key steps in the route include an unprecedented conjugate addition of an indole acetate ester enolate to a nitrosoalkene, and an intramolecular Romo cyclization to generate a  $\beta$ -lactone fused to the requisite *cis*-2-azadecalin needed for the alkaloid. Work is currently underway using the intermediates described here for construction of the bridging oxepane ring directed towards syntheses of the congeneric alkaloids **1** and **2**.<sup>[20]</sup>


Received: October 2, 2012

Published online: November 19, 2012

**Keywords:** alkaloids · lactones · natural products · nitrogen heterocycles · total synthesis

- [1] For reviews, see: a) G. A. Cordell, *Introduction to Alkaloids: A Biogenetic Approach*, Wiley-Interscience, New York, **1981**; b) S. W. Pelletier in *Alkaloids: Chemical and Biological Perspectives, Vol. 1* (Ed.: S. W. Pelletier), Wiley, New York, **1983**; c) N. G. Bisset in *Indoles and Biogenetically Related Alkaloids* (Eds.: J. D. Phillipson, M. H. Zenk), Academic Press, London, **1980**; d) R. B. Herbert in *The Chemistry of Heterocyclic Compounds. Indoles Part 4, The Monoterpenoid Indole Alkaloids* (Ed.: J. E. Saxton), Wiley, New York, **1983**; e) Atta-ur-Rahman, A. Basha, *Biosynthesis of Indole Alkaloids*; Clarendon Press: Oxford, **1983**; f) T. M. Kutchan, *Phytochemistry* **1993**, 32, 493.
- [2] T.-S. Kam, Y.-M. Choo, *Helv. Chim. Acta* **2004**, 87, 366.
- [3] K. Koyama, Y. Hirasawa, K. Zaima, T. C. Hoe, K.-L. Chan, H. Morita, *Bioorg. Med. Chem.* **2008**, 16, 6483.
- [4] For reviews of nitrosoalkenes see: a) T. L. Gilchrist, *Chem. Soc. Rev.* **1983**, 12, 53; b) I. M. Lyapkalo, S. L. Ioffe, *Russ. Chem. Rev.* **1998**, 67, 467.
- [5] a) S. H. Oh, G. S. Cortez, D. Romo, *J. Org. Chem.* **2005**, 70, 2835; b) H. Henry-Riyad, C. Lee, V. C. Purohit, D. Romo, *Org. Lett.* **2006**, 8, 4363; c) G. Ma, H. Nguyen, D. Romo, *Org. Lett.* **2007**, 9, 2143; d) V. C. Purohit, A. S. Matla, D. Romo, *J. Am. Chem. Soc.* **2008**, 130, 10478; e) H. Nguyen, G. Ma, D. Romo, *Chem. Commun.* **2010**, 46, 4803; f) K. A. Morris, K. M. Arendt, S. H. Oh, D. Romo, *Org. Lett.* **2010**, 12, 3764; g) H. Nguyen, G. Ma, T. Gladysheva, T. Fremgen, D. Romo, *J. Org. Chem.* **2011**, 76, 2.
- [6] Taken in part from: M. M. Majireck, Ph.D. Thesis, The Pennsylvania State University, **2011**.
- [7] S. Mahboobi, K. Bernauer, *Helv. Chim. Acta* **1988**, 71, 2034.
- [8] P. S. Chauhan, M. M. Majireck, S. M. Weinreb, *Heterocycles* **2012**, 84, 577.
- [9] D. J. Hlasta, D. Luttinger, M. H. Perrone, M. J. Silbernagel, S. J. Ward, D. R. Haubrich, *J. Med. Chem.* **1987**, 30, 1555.
- [10] This transformation presumably occurs via the azafulvene intermediate **A** derived from the indole. Evidence for this supposition is that if the hydrogenation is conducted in ethanol rather than *tert*-butyl alcohol, a significant amount of the product

**B** results where the acetate group is replaced by ethoxy through interception of **A** by the solvent. This compound is resistant to further catalytic reduction.<sup>[6]</sup>



- [11] We thank Dr. Hemant Yennawar (Penn State Small Molecule X-ray Crystallographic Facility) for the crystal structure determination.
- [12] C. H. DePuy, B. W. Ponder, *J. Am. Chem. Soc.* **1959**, *81*, 4629.
- [13] L. A. G. M. Van den Broek, M. L. Breuer, R. M. J. Liskamp, H. C. J. Ottenheijm, *J. Org. Chem.* **1987**, *52*, 1511.

- [14] We believe the bulky N-Cbz group causes the adjacent ester to assume a conformation which is not favorably disposed stereo-electronically for  $\alpha$ -proton removal by base.
- [15] M. Schlosser, T. Jenny, Y. Guggisberg, *Synlett* **1990**, 704.
- [16] Cf. C. L. Martin, L. E. Overman, J. M. Rohde, *J. Am. Chem. Soc.* **2010**, *132*, 4894.
- [17] See for example: I. T. Huscroft, E. J. Carlson, G. G. Chicchi, M. M. Kurtz, C. London, P. Raubo, A. Wheeldon, J. J. Kulagowski, *Bioorg. Med. Chem. Lett.* **2006**, *16*, 2008.
- [18] B. Nyasse, L. Grehn, U. Ragnarsson, *Chem. Commun.* **1997**, 1017.
- [19] We are grateful to Professor H. Morita (Hoshi University) for copies of the NMR spectra of the TFA salt of the natural alkaloid.
- [20] Although alkaloids **1** and **2** in principle could be prepared by removal of the lactone oxygen atom of **24**, to date we have been unable to execute this transformation. Research is continuing on solving this problem or finding another approach to angustilodine and alstilobanine E.